DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells

Zhang,Lili; Zhang,Shuguang; Li,Aihua; Zhang,Anqi; Zhang,Shiqian; Chen,Liang

doi:10.3892/ijmm.2018.3869

DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells

Authors:
- Lili Zhang
- Shuguang Zhang
- Aihua Li
- Anqi Zhang
- Shiqian Zhang
- Liang Chen
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China, Department of Gynecological Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China
Published online on: September 11, 2018 https://doi.org/10.3892/ijmm.2018.3869
Pages: 3065-3072
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial ovarian cancer (EOC) is one of the most lethal gynecological malignancies and is known to be associated with the accumulation of various genetic and epigenetic alterations. As a member of the human histone‑lysine N‑methyltransferase SETD1A (SET1)/histone‑lysine N‑methyltransferase 2A (MLL) complexes that are required for full SET1/MLL methyltransferase activity, protein dpy‑30 homolog (DPY30) catalyzes histone H3K4 methylation, and its dysfunction has been associated with the occurrence of cancer. Therefore, the present study investigated the role of DPY30 in EOC and the potential association between DPY30 expression and the clinicopathological characteristics of EOC. The expression of DPY30 was examined in EOC tissues and cell lines to identify any correlations between the clinicopathological characteristics of EOC and DPY30 expression, and to determine the effects of DPY30 on EOC cell proliferation, migration and invasion. DPY30 was highly expressed in EOC tissues and cell lines, and high DPY30 expression was significantly associated with notable clinicopathological variables in EOC patients, including International Federation of Gynecology and Obstetrics stage, pathological grade and lymph node metastasis. Functional studies on EOC cell lines demonstrated that DPY30 significantly promoted cell proliferation, migration, and invasion, accelerated cell cycle progression, and promoted epithelial‑mesenchymal transition. Chromatin immunoprecipitation assay results revealed that DPY30 regulates histone H3K4 modification via interaction with the vimentin gene promoter, suggesting that DPY30 promotes the transcription of vimentin. Finally, high expression of DPY30 was significantly associated with reduced survival in patients with EOC. The results indicated that DPY30 may act as an oncogene in EOC and thus represents a potential therapeutic target and prognostic marker in EOC.

View Figures

View References

1	Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer. 11:719–725. 2011. View Article : Google Scholar : PubMed/NCBI
2	Gao L, Ye X, Ma RQ, Cheng HY, Han HJ, Cui H, Wei LH and Chang XH: Low programmed cell death 5 expression is a prognostic factor in ovarian cancer. Chin Med J (Engl). 128:1084–1090. 2015. View Article : Google Scholar
3	Kim MK, James J and Annunziata CM: Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells. BMC Cancer. 15:1962015. View Article : Google Scholar : PubMed/NCBI
4	Bhaumik SR, Smith E and Shilatifard A: Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol. 14:1008–1016. 2007. View Article : Google Scholar : PubMed/NCBI
5	Kouzarides T: Chromatin modifications and their function. Cell. 128:693–705. 2007. View Article : Google Scholar : PubMed/NCBI
6	Berger SL: The complex language of chromatin regulation during transcription. Nature. 447:407–412. 2007. View Article : Google Scholar : PubMed/NCBI
7	Martin C and Zhang Y: The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 6:838–849. 2005. View Article : Google Scholar : PubMed/NCBI
8	Dou Y, Milne TA, Ruthenburg AJ, Lee S, Lee JW, Verdine GL, Allis CD and Roeder RG: Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol. 13:713–719. 2006. View Article : Google Scholar : PubMed/NCBI
9	Shilatifard A: Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol. 20:341–348. 2008. View Article : Google Scholar : PubMed/NCBI
10	Shilatifard A: The COMPASS family of histone H3K4 methylases: Mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem. 81:65–95. 2012. View Article : Google Scholar : PubMed/NCBI
11	Jiang H, Shukla A, Wang X, Chen WY, Bernstein BE and Roeder RG: Role for Dpy-30 in ES cell-fate specification by regulation of H3K4 methylation within bivalent domains. Cell. 144:513–525. 2011. View Article : Google Scholar : PubMed/NCBI
12	Yang Z, Augustin J, Chang C, Hu J, Shah K, Chang CW, Townes T and Jiang H: The DPY30 subunit in SET1/MLL complexes regulates the proliferation and differentiation of hematopoietic progenitor cells. Blood. 124:2025–2033. 2014. View Article : Google Scholar : PubMed/NCBI
13	Simboeck E, Gutierrez A, Cozzuto L, Beringer M, Caizzi L, Keyes WM and Di Croce L: DPY30 regulates pathways in cellular senescence through ID protein expression. EMBO J. 32:2217–2230. 2013. View Article : Google Scholar : PubMed/NCBI
14	Varier RA and Timmers HT: Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta. 1815.75–89. 2011.
15	Chervona Y and Costa M: Histone modifications and cancer: Biomarkers of prognosis. Am J Cancer Res. 2:589–597. 2012.
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
17	Liu Y, Wang Y, Chen C, Zhang J, Qian W, Dong Y, Liu Z, Zhang X, Wang X and Zhang Z: LSD1 binds to HPV16 E7 and promotes the epithelial-mesenchymal transition in cervical cancer by demethylating histones at the Vimentin promoter. Oncotarget. 8:11329–11342. 2017.
18	Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
19	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
20	Yang J and Weinberg RA: Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
21	Steward MM, Lee JS, O’Donovan A, Wyatt M, Bernstein BE and Shilatifard A: Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. Nat Struct Mol Biol. 13:852–854. 2006. View Article : Google Scholar : PubMed/NCBI
22	Lee YJ, Han ME, Baek SJ, Kim SY and Oh SO: Roles of DPY30 in the proliferation and motility of gastric cancer cells. PLoS One. 10:e013–1863. 2015.
23	Knösel T, Schlüns K, Stein U, Schwabe H, Schlag PM, Dietel M and Petersen I: Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer. Neoplasia. 6:23–28. 2004. View Article : Google Scholar : PubMed/NCBI
24	Shi Y and Whetstine JR: Dynamic regulation of histone lysine methylation by demethylases. Mol Cell. 25:1–14. 2007. View Article : Google Scholar : PubMed/NCBI
25	South PF, Fingerman IM, Mersman DP, Du HN and Briggs SD: A conserved interaction between the SDI domain of Bre2 and the Dpy-30 domain of Sdc1 is required for histone methylation and gene expression. J Biol Chem. 285:595–607. 2010. View Article : Google Scholar :
26	Takahashi YH, Westfield GH, Oleskie AN, Trievel RC, Shilatifard A and Skiniotis G: Structural analysis of the core COMPASS family of histone H3K4 methylases from yeast to human. Proc Natl Acad Sci USA. 108:20526–20531. 2011. View Article : Google Scholar : PubMed/NCBI
27	Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G and Hara E: Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature. 409:1067–1070. 2001. View Article : Google Scholar : PubMed/NCBI